Left Atrial Appendage Closure Compared With Oral Anticoagulants for Patients With Atrial Fibrillation: A Systematic Review and Network Meta‐Analysis
Authors:
Open Access
- 20 August 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (16) , e034815
Abstract
Background: Percutaneous left atrial appendage closure (LAAC) has been suggested as an alternative to long‐term oral anticoagulation for nonvalvular atrial fibrillation, but comparative data remain scarce. We aimed to assess ischemic and bleeding outcomes of LAAC compared with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) for the prevention of cardioembolic events in patients with atrial fibrillation. Methods and Results: Embase and MEDLINE were searched for randomized trials comparing LAAC, VKAs, and DOACs. The primary efficacy end point was any stroke or systemic embolism. Treatment effects were calculated from a network meta‐analysis and ranked according to the surface under the cumulative ranking curve. Seven trials and 73 199 patients were included. The risk of the primary end point was not statistically different between LAAC versus VKAs (odds ratio [OR], 0.92 [95% CI, 0.62–1.50]) and LAAC versus DOACs (OR, 1.11 [95% CI, 0.71–1.73]). LAAC and DOACs resulted in similar risk of major or minor (OR, 0.93 [95% CI, 0.61–1.42]) and major bleeding (OR, 0.92 [95% CI, 0.58–1.46]); however, after exclusion of procedural bleeding, bleeding risk was significantly lower in those undergoing LAAC. Both LAAC and DOACs reduced the risk of all‐cause death compared with VKAs (LAAC versus VKAs: OR, 0.70 [95% CI, 0.53–0.91]; DOACs versus VKAs: OR, 0.90 [95% CI, 0.85–0.95], respectively). DOACs ranked as the best treatment for stroke or systemic embolism prevention (66.9%) and LAAC for reducing major bleeding (63.9%) and death (96.4%). Conclusions: As a nonpharmacological alternative to oral anticoagulation for atrial fibrillation, LAAC showed similar efficacy and safety compared with VKAs or DOACs. Prospective confirmation from larger studies is warranted.Keywords
This publication has 46 references indexed in Scilit:
- Meta-Analysis Comparing Left Atrial Appendage Occlusion, Direct Oral Anticoagulants, and Warfarin for Nonvalvular Atrial FibrillationThe American Journal of Cardiology, 2022
- Clinical outcomes of left atrial appendage occlusion versus direct oral anticoagulation in patients with atrial fibrillation and prior ischemic stroke: A propensity-score matched studyInternational Journal of Cardiology, 2022
- Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillationClinical Research in Cardiology, 2022
- Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population‐based cohort studiesPharmacoepidemiology and Drug Safety, 2021
- Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trialHeart Rhythm, 2017
- Post-Approval U.S. Experience With Left Atrial Appendage Closure for Stroke Prevention in Atrial FibrillationJACC, 2017
- Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial FibrillationJAMA, 2014
- Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin TherapyJACC, 2014
- Left Atrial Appendage Closure With the Watchman Device in Patients With a Contraindication for Oral AnticoagulationJACC, 2013
- Detection of Previously Undiagnosed Atrial Fibrillation in Patients With Stroke Risk Factors and Usefulness of Continuous Monitoring in Primary Stroke PreventionThe American Journal of Cardiology, 2012